Selinexor as a Therapeutic Target: Advances in Non-small Cell and Small Cell Lung Cancer Treatment Strategies

Bosheng Zheng; Wenqi Zhang; Shaonan Xie; Yaqing Han; Guangjie Liu; Yanjie Liu; Maogang Gao; Shize Wang; Qingyi Liu

doi:10.2174/0115748928322627241016120142

Selinexor as a Therapeutic Target: Advances in Non-small Cell and Small Cell Lung Cancer Treatment Strategies

Recent Pat Anticancer Drug Discov. 2024 Oct 29. doi: 10.2174/0115748928322627241016120142. Online ahead of print.

Authors

Bosheng Zheng¹, Wenqi Zhang², Shaonan Xie¹, Yaqing Han¹, Guangjie Liu¹, Yanjie Liu¹, Maogang Gao¹, Shize Wang¹, Qingyi Liu¹

Affiliations

¹ Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
² Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

PMID: 39473203
DOI: 10.2174/0115748928322627241016120142

Abstract

Selinexor treats lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This review summarizes the prevalence and types of lung cancer and emphasizes the challenges associated with current treatments like resistance and limited effectiveness. Selinexor is a selective inhibitor of nuclear export (SINE) that has emerged as a potential therapy that targets the nuclear export of tumor suppressor proteins. The mechanisms of selinexor, its potential in combination therapies, and challenges like side effects and drug resistance are explained in this review. Key findings highlight the effectiveness of selinexor in preclinical studies, particularly against KRAS-mutant NSCLC and in combination with chemotherapy for SCLC. The review concludes with a discussion of future directions and underscores the potential of selinexor to improve the treatment strategies for lung cancer.

Keywords: NSCLC; SCLC; SINE.; Selinexor; XPO1; lung cancer.